CL2014000492A1 - Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras - Google Patents

Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras

Info

Publication number
CL2014000492A1
CL2014000492A1 CL2014000492A CL2014000492A CL2014000492A1 CL 2014000492 A1 CL2014000492 A1 CL 2014000492A1 CL 2014000492 A CL2014000492 A CL 2014000492A CL 2014000492 A CL2014000492 A CL 2014000492A CL 2014000492 A1 CL2014000492 A1 CL 2014000492A1
Authority
CL
Chile
Prior art keywords
pirdine
oxadiazol
imidazo
carboxamide
carbamoyl
Prior art date
Application number
CL2014000492A
Other languages
English (en)
Spanish (es)
Inventor
Valentina Molteni
Jon Loren
Hank Michael James Petrassi
Xiaolin Li
Xiadong Liu
Juliet Nabakka
Bao Nguye
Vince Yeh
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CL2014000492A1 publication Critical patent/CL2014000492A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014000492A 2011-09-01 2014-02-27 Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras CL2014000492A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
CL2014000492A1 true CL2014000492A1 (es) 2014-10-03

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000492A CL2014000492A1 (es) 2011-09-01 2014-02-27 Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras

Country Status (30)

Country Link
US (3) US8569283B2 (enExample)
EP (1) EP2751104B1 (enExample)
JP (1) JP6134319B2 (enExample)
KR (1) KR101962495B1 (enExample)
CN (1) CN103797011B (enExample)
AP (1) AP2014007493A0 (enExample)
AR (1) AR087753A1 (enExample)
AU (1) AU2012302042B2 (enExample)
BR (1) BR112014004560A2 (enExample)
CA (1) CA2845169C (enExample)
CL (1) CL2014000492A1 (enExample)
CO (1) CO6900141A2 (enExample)
CR (1) CR20140107A (enExample)
CU (1) CU20140024A7 (enExample)
EA (1) EA026152B1 (enExample)
ES (1) ES2761332T3 (enExample)
GT (1) GT201400034A (enExample)
IL (1) IL231227A0 (enExample)
MA (1) MA35460B1 (enExample)
MX (1) MX339937B (enExample)
PE (1) PE20140909A1 (enExample)
PH (1) PH12014500372A1 (enExample)
PL (1) PL2751104T3 (enExample)
PT (1) PT2751104T (enExample)
SG (1) SG2014014369A (enExample)
TN (1) TN2014000068A1 (enExample)
TW (1) TW201313717A (enExample)
UY (1) UY34301A (enExample)
WO (1) WO2013033167A1 (enExample)
ZA (1) ZA201401175B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509424B2 (en) 2019-12-13 2025-12-30 Nippon Shinyaku Co., Ltd. Compound and composition as PDGF receptor kinase inhibitor

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
AP2014007493A0 (en) 2011-09-01 2014-03-31 Irm Llc Compounds and compositions as C-KIT kinase inhibitors
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015054574A1 (en) 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR102710552B1 (ko) 2015-07-02 2024-09-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균 화합물
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
US20190256509A1 (en) * 2016-06-08 2019-08-22 Chrysalis, Inc. Histone demethylase inhibitors
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
EP3532063A4 (en) 2016-10-27 2020-07-22 Pulmokine, Inc. POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
KR20240053077A (ko) 2017-03-01 2024-04-23 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 병용 요법
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11939320B2 (en) 2017-11-02 2024-03-26 Abbvie Inc. Modulators of the integrated stress pathway
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020274564A1 (en) * 2019-05-13 2021-12-09 Novartis Ag Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide
US12187703B2 (en) 2019-05-13 2025-01-07 Novartis Ag Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
ES2978573T3 (es) 2019-09-13 2024-09-16 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4181921A4 (en) 2020-07-15 2025-02-26 Third Harmonic Bio, Inc. CRYSTALLINE FORMS OF A SELECTIVE C-KIT KINASE INHIBITOR
TW202237097A (zh) 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
EP4308239A1 (en) 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3212074A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022194905A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
IL312366A (en) 2021-10-28 2024-06-01 Janssen Sciences Ireland Unlimited Co Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
EP4626884A1 (en) * 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
AU2023390239A1 (en) * 2022-12-07 2025-07-24 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
JP2025541191A (ja) * 2022-12-07 2025-12-18 サード ハーモニック バイオ， インコーポレイテッド Ｃ－ｋｉｔキナーゼ阻害剤としての化合物及び組成物
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
CA2591321C (en) 2004-09-09 2013-09-24 Natco Pharma Limited Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP2010509349A (ja) * 2006-11-03 2010-03-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP6117104B2 (ja) * 2010-11-15 2017-04-19 アッヴィ・インコーポレイテッド Ｎａｍｐｔおよびｒｏｃｋ阻害薬
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
WO2013033203A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2013033620A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
AP2014007493A0 (en) 2011-09-01 2014-03-31 Irm Llc Compounds and compositions as C-KIT kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12509424B2 (en) 2019-12-13 2025-12-30 Nippon Shinyaku Co., Ltd. Compound and composition as PDGF receptor kinase inhibitor

Also Published As

Publication number Publication date
MA35460B1 (fr) 2014-09-01
CA2845169A1 (en) 2013-03-07
EA026152B1 (ru) 2017-03-31
GT201400034A (es) 2015-02-19
EA201490545A1 (ru) 2014-07-30
US8754071B2 (en) 2014-06-17
KR20140075692A (ko) 2014-06-19
AP2014007493A0 (en) 2014-03-31
CR20140107A (es) 2014-05-02
AR087753A1 (es) 2014-04-16
CN103797011A (zh) 2014-05-14
MX339937B (es) 2016-06-17
AU2012302042A1 (en) 2014-04-17
MX2014002484A (es) 2014-11-25
PL2751104T3 (pl) 2020-04-30
EP2751104A1 (en) 2014-07-09
PH12014500372A1 (en) 2014-04-07
AU2012302042B2 (en) 2016-03-31
EP2751104B1 (en) 2019-09-25
PE20140909A1 (es) 2014-07-20
WO2013033167A1 (en) 2013-03-07
JP2014525448A (ja) 2014-09-29
CU20140024A7 (es) 2014-04-24
CN103797011B (zh) 2016-03-30
US20140031333A1 (en) 2014-01-30
US20130059832A1 (en) 2013-03-07
ES2761332T3 (es) 2020-05-19
CA2845169C (en) 2022-04-19
UY34301A (es) 2013-04-05
TW201313717A (zh) 2013-04-01
CO6900141A2 (es) 2014-03-20
IL231227A0 (en) 2014-04-30
TN2014000068A1 (en) 2015-07-01
US9023839B2 (en) 2015-05-05
BR112014004560A2 (pt) 2017-04-04
US8569283B2 (en) 2013-10-29
SG2014014369A (en) 2014-09-26
KR101962495B1 (ko) 2019-03-26
JP6134319B2 (ja) 2017-05-24
ZA201401175B (en) 2015-01-28
US20140228347A1 (en) 2014-08-14
PT2751104T (pt) 2019-12-16

Similar Documents

Publication Publication Date Title
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
CL2014000299A1 (es) Compuestos derivados de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2.2.1]heptan-3-carboxamidas sustituidas, inhibidores de catepsina c; composicion farmaceutica; metodo de tratamiento o prevencion; y uso para el tratamiento de enfermedades tales como asma, enfermedades alergicas, artritis reumatoidea y aterosclerosis, entre otras.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
NI201200072A (es) Métodos y composiciones para tratar cáncer
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
CL2014000203A1 (es) Compuestos derivados de piridin-2(1h) -ona, inhibidores de jak; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de enfermedades mieloproliferativas, leucemia,artritid reumatoide, asma, esclerosis multiplem, entre otras.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
PT3184523T (pt) Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
CL2014001090A1 (es) Compuestos derivados de oxazolidinona biciclica; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como aterosclerosis y dislipidemia.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MX391445B (es) Formas cristalinas de 3-(imidazol[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2007003187A1 (es) Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2013004995A8 (en) Pyrimidinone compounds and their use
WO2013100566A8 (en) Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same